Previous 10 | Next 10 |
CINCINNATI, April 30, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathI...
CINCINNATI, April 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecul...
CINCINNATI, April 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldas...
CINCINNATI, April 14, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19. Since the emergence of COVID-19 outbreaks in January, Meridian has suppor...
Meridian Bioscience (NASDAQ: VIVO ) provides a business update including preliminary Q2 2020 revenue. More news on: Meridian Bioscience, Inc., Healthcare stocks news, Read more ...
CINCINNATI, April 02, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020. Preliminary ...
An investment thesis in Meridian Bioscience (VIVO) would be based on its success to date in its transformation efforts as well as its potential for acquisition. Meridian Bioscience Meridian Bioscience manufactures and distributes diagnostic platforms, tests, and biologics. The company is...
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of mol...
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 148 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...